Conatus Gets Pfizer Subsidiary

Xconomy San Diego — 

Conatus Pharmaceuticals, a San Diego-based drug developer targeting liver disease and cancer, announced it has acquired Pfizer subsidiary Idun Pharmaceuticals for an undisclosed sum. Conatus was launched in 2005 by Idun execs after Pfizer acquired the firm, which at the time was developing liver disease treatments and oncology drugs, and held intellectual property in the area of apoptosis. “Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology,” said Conatus CEO Steven Mento of the company’s acquisition of Idun.